Bionano Laboratories Announces New Category I CPT Code For OGM Use In Hematological Malignancy Analysis, Expected To Be Included In The Next CPT Codebook And To Be Effective January 1, 2025
Portfolio Pulse from Benzinga Newsdesk
Bionano Laboratories, a division of Bionano Genomics, Inc. (NASDAQ:BNGO), announced that the American Medical Association (AMA) has established a new Category I CPT code for the use of optical genome mapping (OGM) in hematological malignancy analysis. This code is expected to be included in the next CPT codebook and effective from January 1, 2025, facilitating reimbursement for the OGM-Dx™ HemeOne test.
June 17, 2024 | 8:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bionano Genomics, Inc. (BNGO) announced a new Category I CPT code for their optical genome mapping (OGM) technology, effective January 1, 2025. This development is crucial for obtaining reimbursement for their OGM-Dx™ HemeOne test.
The establishment of a new Category I CPT code by the AMA is a significant regulatory milestone for Bionano Genomics. It will facilitate reimbursement from third-party payers for their OGM-Dx™ HemeOne test, potentially increasing adoption and revenue.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100